نتائج البحث - "Schuette, Jochen"

1

دورية أكاديمية

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

المؤلفون: Joensuu, Heikki, Wardelmann, Eva, Eriksson, Mikael, Reichardt, Annette, Hall, Kirsten Sundby, Schütte, Jochen, Cameron, Silke, Hohenberger, Peter, Sihto, Harri, Jost, Philipp J., Lindner, Lars H., Bauer, Sebastian, Nilsson, Bengt, Kallio, Raija, Pesonen, Tommi, Reichardt, Peter

المساهمون: Research Programs Unit, Department of Oncology, Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center, Department of Pathology, HUSLAB

مصطلحات موضوعية: 3122 Cancers, Italian sarcoma group, Mesylate, Efficacy, Safety

وصف الملف: application/pdf

العلاقة: Joensuu , H , Wardelmann , E , Eriksson , M , Reichardt , A , Hall , K S , Schütte , J , Cameron , S , Hohenberger , P , Sihto , H , Jost , P J , Lindner , L H , Bauer , S , Nilsson , B , Kallio , R , Pesonen , T & Reichardt , P 2023 , ' KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial ' , Clinical Cancer Research , vol. 29 , no. 17 , pp. 3313–3319 . https://doi.org/10.1158/1078-0432.CCR-22-3980Test; Bibtex: 10.1158/1078-0432.CCR-22-3980; ORCID: /0000-0003-0281-2507/work/142855600; ORCID: /0000-0001-5265-5509/work/142855612; 0a449837-f2ba-4992-bdb3-5aedf5005c35; http://hdl.handle.net/10138/565514Test; 001067264900001

الإتاحة: http://hdl.handle.net/10138/565514Test

View record in BASE

2

دورية أكاديمية

Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.

المؤلفون: Joensuu, Heikki, Reichardt, Annette, Eriksson, Mikael, Hohenberger, Peter, Boye, Kjetil, Cameron, Silke, Lindner, Lars H, Jost, Philipp J, Bauer, Sebastian, Schütte, Jochen, Lindskog, Stefan, Kallio, Raija, Jaakkola, Panu M, Goplen, Dorota, Wardelmann, Eva, Reichardt, Peter

المصدر: Br J Cancer ; ISSN:1532-1827

العلاقة: https://doi.org/10.1038/s41416-024-02738-zTest; https://pubmed.ncbi.nlm.nih.gov/38862742Test

الإتاحة: https://doi.org/10.1038/s41416-024-02738-zTest
https://pubmed.ncbi.nlm.nih.gov/38862742Test

View record in BASE

3

دورية أكاديمية

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors ; An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

المؤلفون: Joensuu, Heikki, Eriksson, Mikael, Sundby Hall, Kirsten, Reichardt, Annette, Hermes, Barbara, Schütte, Jochen, Cameron, Silke, Hohenberger, Peter, Jost, Philipp J., Al-Batran, Salah-Eddin, Lindner, Lars H., Bauer, Sebastian, Wardelmann, Eva, Nilsson, Bengt, Kallio, Raija, Jaakkola, Panu, Junnila, Jouni, Alvegård, Thor, Reichardt, Peter

المصدر: JAMA Oncology ; volume 6, issue 8, page 1241 ; ISSN 2374-2437

الإتاحة: https://doi.org/10.1001/jamaoncol.2020.2091Test
https://jamanetwork.com/journals/jamaoncology/articlepdf/2766796/jamaoncology_joensuu_2020_oi_200029_1597168363.06787.pdfTest

View record in BASE

4

Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib

المصدر: Cancer. 120(15):2325-2333

مصطلحات موضوعية: gastrointestinal stromal tumor, imatinib, adjuvant therapy, predictive, score, Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi, Medical and Health Sciences, Clinical Medicine, Cancer and Oncology

وصف الملف: electronic

الوصول الحر: https://lup.lub.lu.se/record/4659548Test
https://portal.research.lu.se/files/2516952/5276946Test
http://dx.doi.org/10.1002/cncr.28669Test

View record in SwePub

5

دورية أكاديمية

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

المؤلفون: Reichardt, Peter, Demetri, George D., Gelderblom, Hans, Rutkowski, Piotr, Im, Seock-Ah, Gupta, Sudeep, Kang, Yoon-Koo, Schoffski, Patrick, Schuette, Jochen, Soulieres, Denis, Blay, Jean-Yves, Goldstein, David, Fly, Kolette, Huang, Xin, Corsaro, Massimo, Lechuga, Maria Jose, Martini, Jean-Francois, Heinrich, Michael C.

المساهمون: 임석아, Im, Seock-Ah

مصطلحات موضوعية: TYROSINE KINASE INHIBITOR, IMATINIB RESISTANCE, ACQUIRED-RESISTANCE, GROWTH-FACTOR, ACTIVATION, SU11248, EFFICACY, MECHANISMS, GENOTYPE, MESYLATE, Sunitinib, Imatinib, GIST, KIT, KIT mutation, Imatinib-resistant GIST, Overall survival, Progression-free survival

العلاقة: BMC Cancer, Vol.16, p. 22; 44853; https://hdl.handle.net/10371/100530Test; 000368077400002; 2-s2.0-84954328203

الإتاحة: https://doi.org/10.1186/s12885-016-2051-5Test
https://hdl.handle.net/10371/100530Test

View record in BASE

النص الكامل

6

دورية أكاديمية

Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib

المساهمون: Clinicum, Department of Oncology, Department of Pathology, Haartman Institute (-2014), Translational Cancer Biology (TCB) Research Programme, Heikki Joensuu / Principal Investigator

مصطلحات موضوعية: Cancers

وصف الملف: application/pdf

العلاقة: Joensuu , H , Eriksson , M , Hall , K S , Hartmann , J T , Pink , D , Schuette , J , Ramadori , G , Hohenberger , P , Duyster , J , Al-Batran , S-E , Schlemmer , M , Bauer , S , Wardelmann , E , Sarlomo-Rikala , M , Nilsson , B , Sihto , H , Ballman , K V , Leinonen , M , DeMatteo , R P & Reichardt , P 2014 , ' Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib ' , Cancer , vol. 120 , no. 15 , pp. 2325-2333 . https://doi.org/10.1002/cncr.28669Test; Bibtex: urn:9f9b6887f8b22ef46a3c9ea4758078db; ORCID: /0000-0003-0281-2507/work/29959772; ORCID: /0000-0001-5265-5509/work/116550037; http://hdl.handle.net/10138/208487Test; 935e2344-84aa-4e4f-98c3-1e7ee51b0710; 84904759514; 000340241500015

الإتاحة: http://hdl.handle.net/10138/208487Test

View record in BASE